Maven Securities LTD acquired a new stake in Unity Biotechnology, Inc. (NASDAQ:UBX – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $40,000.
Several other institutional investors also recently made changes to their positions in UBX. Acadian Asset Management LLC grew its holdings in shares of Unity Biotechnology by 39.8% during the first quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock valued at $435,000 after purchasing an additional 111,097 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Unity Biotechnology by 5.6% during the second quarter. Renaissance Technologies LLC now owns 957,718 shares of the company’s stock valued at $540,000 after purchasing an additional 51,003 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Unity Biotechnology by 25.4% during the second quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock valued at $35,000 after purchasing an additional 12,681 shares during the last quarter. State Street Corp grew its holdings in shares of Unity Biotechnology by 21.0% during the second quarter. State Street Corp now owns 130,440 shares of the company’s stock valued at $74,000 after purchasing an additional 22,600 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Unity Biotechnology during the third quarter worth approximately $201,000.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on UBX. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Unity Biotechnology in a research report on Wednesday, February 15th. Mizuho reduced their price objective on Unity Biotechnology from $80.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, November 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $34.50.
Unity Biotechnology Stock Performance
About Unity Biotechnology
Unity Biotechnology, Inc operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on Unity Biotechnology (UBX)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology, Inc. (NASDAQ:UBX – Get Rating).
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.